Biology & Medicine

biology and medicine
Low-Cost, Disposable Device for Manufacture Car T-Cells for Cancer Therapy (RFT-538)

Scientists at NDSU have developed a new device for a scalable, biomanufacturing platform for the production of CAR-modified T-cells while eliminating on-target/off-tumor toxicity and decreasing the current production cost by 500 times (per treatment).  The technology relates to a device to produce modified T-cells comprising a first chamber for proliferating a population of T-cells and a second chamber for modifying the T-cells to express a desired T-cell receptor antigen.  The modified CAR T-cells can be used to treat cancer. 

Block-Scaffolds for Bone Regeneration using Nanoclay-Polycaprolactone Scaffolds with Supplements (RFT-533) 

Scientists at NDSU have developed a flexible, modular, bone scaffold for filling large bone gaps and accelerating bone growth with various additives, such as nutrients, cytokines, therapeutics and minerals incorporated into the scaffold.  The scaffold is made of a clay and a polymer.

Double Extra-Aortic Counterpropulsion Device (RFT-532)

Scientists at NDSU have developed a double extra-aortic cuff to treat heart failure.  Counterpulsation devices (CPDs) have been the most widely used mechanical circulatory support (MCS) devices for treating heart failure (HF) patients. However, these CPDs provide insufficient cardiac output (CO) to meet the needs of New York Health Association (NYHA) ambulatory class IV HF patients. During extra-aortic CPD deflation, retrograde flow may result that reduces the forward kinetic energy (KE) of the aortic flow (AOF) which reduces the potential improvement in CO. To enhance the physiological benefits extra-aortic CPDs we have designed a non-blood contacting extra-aortic two-segmented CPD that can optimize the KE of the AOF and provide additional increase CO to patients’ lives.  

Devices and Methods for Producing Synthetic Silk with Superior Characteristics (RFT-505)

Scientists at NDSU have developed a device and methods to produce spider silk that has the ability to produce silk similar to the silk produced by a spider. Our device mimics the pH and ionic gradients found in the natural gland., but also pulls the fiber from the device as opposed to extruding it via pushing.  This replicates native shear forces that are important for proper alignment of silk proteins. The result is a solid silk fiber that integrates the natural elements of fiber production (i.e. pressure, pH, and ionic gradients) to more accurately replicate the spider's ability to produce silk. Additionally, application of an electric field to the microfluidic device is a unique combination of microfuidic spinning and electrospinning to create a better fiber.

Stem Cell Mobilization Boosted 10X to 100X in People with Inadequate Response to Stem Cell Mobilizing Drugs (RFT-495)

Scientists at NDSU have developed a method to increase the efficacy of certain stem cell mobilizing drugs, including G-CSF and AMD3100. The method involves blocking the leptin receptor concurrent with administration of these drugs. In experimental studies, this strategy increased mobilization of the currently available mobilizing agents two- to five-fold higher than that observed with the agent alone, accounting for an overall mobilizing increase of ten- to one hundred-fold above baseline, depending on the agent used and treatment regimen. This technology has promise to improve outcomes for individuals with diabetes, and others whose stem cell mobilization is less than desired when taking the drugs described above.

Method for Improving the Quality and Quantity of Offspring in Mammals (RFT-494)

Scientists at NDSU have developed a method for predicting and/or confirming the success of pregnancy and/or litter size in mammals as well as devices for field testing of mammal samples for pregnancy success and reproduction prosperity (fecundity).  Measuring hematocrit levels or blood oxygen saturation near the time of insemination of a mammal can indicate the likelihood of a successful pregnancy and also predict litter size.  These methods can also be used to confirm a successful pregnancy sooner than other methods.  

Targeted Delivery and Rapid Release of Anti-Cancer Drugs in Tumors (RFT-470)

NDSU Scientists have developed a liposome-based delivery method with potential to reduce chemotherapy side effects while maintaining or even increasing cancer drug efficacy. The liposome is stabilized in the bloodstream using polyethylene glycol (PEG) and remains stable in the vicinity of healthy cells. However, upon arrival at a tumor the liposome rapidly disintegrates, releasing its contents to be taken up by tumor cells. This disintegration is triggered by conditions found in the tumor extracellular matrix (ECM), specifically the reducing conditions and the presence of Matrix Metalloproteinase 9 (MMP-9). As a result, these liposomes can carry drugs and imaging agents to tumors, releasing them so that a high concentration is available for rapid uptake into tumor cells, and reducing the amount of time these agents spend in the circulatory system or in the vicinity of healthy cells. A reduction in tumor growth was observed using this technology to deliver drugs in a mouse model of pancreatic cancer.

Porcine Circovirus Strain 2 (PCV2) Vaccines and Diagnostic (RFT-468)

Scientists at NDSU have mapped the putative protective and non-protective regions of the PCV2 capsid protein. The key concept for this disclosure is that eliminating or altering the non-protective regions resulted in creation of negative selection markers for the development of the DIVA immunoassay. Additionally, removal of non-protective regions to rationally redesign the antigen is expected to improve vaccine efficacy against both PCV2a and b subtypes and reduce viral shedding, when compared to exisitng vaccines. 

Monoclonal Antibody Against the Receptor for Advanced Glycation Endproducts (mRAGE) (RFT-432)

Scientists at NDSU have developed a monoclonal antibody that inhibits activation of the receptor for advanced glycation end products (RAGE). The antibody binds the V-domain to block activation of RAGE by its ligands. This domain is capable of binding to multiple structurally and functionally diverse ligands, all of which trigger signal transduction by RAGE’s cytosolic domain, and results in sustained inflammation that is associated with diabetes, cancers, Alzheimer’s, multiple sclerosis, and other diseases associated with chronic inflammation. As a result, the anti-RAGE monoclonal antibodies have potential to treat a wide variety of diseases.

Anti-RAGE Monoclonal for Research Use (RFT-432b)

This technology is a monoclonal antibody recognizing the V domain of the receptor for advanced glycation endproducts (RAGE).  RAGE is emerging as a biomarker in many human diseases such as diabetes, cancer and Alzheimer's disease.  In animal models, antibodies against RAGE have shown to reduce RAGE deleterious signaling.  RAGE is a cell-surface receptor that is activated by several ligands.  RAGE is therefore a suitable target for monoclonal antibodies.  We have generated monoclonal antibodies with the aim of blocking RAGE/ligand interaction and decreasing RAGE deleterious effects in several human diseases.  

Improved Ankle Replacement Device and Method (RFT-427)

NDSU engineers have developed an improved design and material for Total Ankle Replacements (TARs) that features an inverted design, in which the concave portion of the joint is on the bottom, and the convex on the top. This inverted design and the mode of assembly and implantation offers several benefits to surgeons and patients.

Novel PEGylated Compounds and Process for Making Antifouling/Biocompatible Materials (RFT-380)

Surfaces having non-fouling characteristics are of great interest for the development of advanced materials in many different applications. In medical device applications, protein attachment can cause any number of unwanted immune reactions when exogenous materials are implanted into biological systems. Materials developed with polyethylene glycols, often referred to as PEGylated materials, are of great interest due to their protein resistance and nontoxic properties.

One of the most widely used biomaterials is Polyurethane, due to its biocompatibility and its mechanical properties. Researchers at NDSU have developed a new class of PEGylated polyurethane materials using a novel process which is much more effective than traditional procedures. The resulting compounds are novel siloxane-PEG copolymers having terminal amine functionality and a backbone of siloxane having a varied number of pendant hydrophilic PEG chains. The low surface energy siloxane can aid in bringing PEG chains to the surface, and the terminal amine functionality can be bound into the polyurethane by reaction with isocyanate. Therefore, the surface of the material will be amphiphilic while the underlying polyurethane bulk will give toughness to the system. This approach allows for precise control over the number of hydrophobic PEG chains, siloxane and PEG chain lengths, and terminal amine functionality.

Linear Glycidyl Carbamate (GC) Resins for Highly Flexible Coatings (RFT-271)

Scientists at North Dakota State University have invented a Low-VOC, chromate-free, solventborne, low viscosity, highly flexible coating resin system. This resin system has the functionality of an epoxy resin while providing the performance of a polyurethane coating without exposing the end-user to isocyanates. When crosslinked with amines, these GC coatings have excellent adhesion, hardness, solvent resistance, gloss, and flexibility on cold-rolled steel and aluminum substrates. This polymer technology was specifically developed to be used to obtain highly flexible coatings while maintaining good solvent and chemical resistance.

Drug Delivery Vehicle for Treatment of Glaucoma and Other Eye Diseases (RFT-263)

Scientists at NDSU (in collaboration with University of Central Florida) have developed a potential ophthalmic drug delivery vehicle for treatment of glaucoma and other ocular diseases. The method uses functionalized cerium oxide nanoparticles (nanoceria), which can be combined with small molecule active ingredients to form a complex that facilitates higher efficiency delivery of drugs into the eye. This technology may provide an alternative to injections for delivering medicines into the eye.

The mechanism of improved drug delivery is thought to be the longer residence time on the eye surface, combined with sustained release that will be promoted using nanoceria. Together, these features are expected to provide significantly enhanced delivery of active ingredients to their site of action. Additionally, a fluorophore can be attached to nanoceria, to enable the tracking of the nanoparticles.

‘Dual Action’ Anti-Microbial Coatings For Implantable Medical Devices (RFT-260)

Scientists at North Dakota State University have invented a unique ‘dual action’ anti-microbial polysiloxane coating that has the capability of exhibiting long-term antimicrobial activity on implantable medical devices. The coatings have a leachable silver-based antimicrobial domain in conjunction with a surface-bound contact active microbial agent - Quaternary Ammonium salt (QAS) that exhibits the two levels of antimicrobial protection. While the covalently bound QAS groups inhibits bio-film formation by microorganisms that come into contact with the coating prior to insertion of the devices into the body, the leachable antimicrobial agent inhibits bio-film formation by microorganisms in the vicinity of the device.

Antibacterial Siloxane Polymer Containing Tethered Anti-Microbial Agent (RFT-232)

Scientists at NDSU (in collaboration with University of Central Florida) have developed a potential ophthalmic drug delivery vehicle for treatment of glaucoma and other ocular diseases. The method uses functionalized cerium oxide nanoparticles (nanoceria), which can be combined with small molecule active ingredients to form a complex that facilitates higher efficiency delivery of drugs into the eye. This technology may provide an alternative to injections for delivering medicines into the eye.

The mechanism of improved drug delivery is thought to be the longer residence time on the eye surface, combined with sustained release that will be promoted using nanoceria. Together, these features are expected to provide significantly enhanced delivery of active ingredients to their site of action. Additionally, a fluorophore can be attached to nanoceria, to enable the tracking of the nanoparticles.

Unique Anti-Fouling and Anti-Microbial Coatings for Marine Applications (RFT-214)

This invention pertains to the development of stable polymeric anti-fouling surface coating formulation that contains Quaternary Ammonium Salts (QAS) as the primary disinfectant.

Novel Environment Friendly Coatings for Marine and Medical Applications (RFT-179)

Scientists at North Dakota State University have combined biocidal and fouling release activities into a single polymeric formulation to develop a unique environmentally friendly coating that holds promise in both marine and medical applications. This novel formulation consists of biocidal moieties that are tethered to its polymer matrix, which in turn prevent them from leaching into the environment.

Studies have demonstrated this biocidal moiety to be capable of killing several types of marine organisms that come in contact with the coating surface. Their complementary fouling release property enables those marine organisms not affected by the biocide to be easily sloughed off.

Besides marine applications, this coating has been shown to render anti-microbial properties on medical devices.

Novel Chemotherapeutic Agents for Anti-Tumor and Anti-Cancer Drugs (RFT-72)

This invention relates to novel, substituted (functionalized) polysiloxane compositions (and methods for synthesis of same) that may be useful as antineoplastics (chemotherapeutics) or other therapeutic agents. Since compositions of this type can transverse cellular membranes, they may also serve as delivery vehicles for other agents with biological activities in both animals and plants (e.g., drugs, herbicides, fungicides, anti-microbials, etc.).

Method of Preparation of ß-Amino Acids (RFT-28)

A method to prepare high purity compounds of either the (R) or (S) enantiomers of ß-amino acids.

Prophylactic, Therapeutic, and Diagnostic Remedy for Treatment of Colibacillosis Infection (RFT-21)

Scientists at North Dakota State University have cloned and sequenced the iss (increased serum survival) gene from virulent avian Escherichia coli strains and expressed its encoded ISS polypeptide sequence. This has enabled them to conduct studies in understanding the gene’s potential and devise strategies to detect and control the colibacillosis infection that the gene is believed to cause.

This invention pertains to the application of this study in formulating DNA vaccines and immunogenic compositions for providing adequate prophylactic, therapeutic and diagnostic remedies against the colibacillosis infection in humans and avian organisms.